242 related articles for article (PubMed ID: 37749594)
1. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
3. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
4. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer.
Zhang P; Dai J; Sun F; Xia H; He W; Duan L; Liu M; Zhao D; Zhu Y; Jiang G
Ann Thorac Surg; 2022 Sep; 114(3):949-958. PubMed ID: 35176262
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
8. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.
Shi L; Meng Q; Tong L; Li H; Dong Y; Su C; Liu Z
Front Oncol; 2022; 12():956755. PubMed ID: 36313678
[TBL] [Abstract][Full Text] [Related]
9. A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Zhou L; Xiong Y; Wang Y; Meng Y; Zhang W; Shen M; Zhang X; Li S; Ren B; Li R; Han Y; Zhang J; Cao S; Du W; Sun Q; Wei F; An X; Yang L; Zhang Y; Ma W; Xu W; Zhang Y; Jiang J; Xu X; Xia J; Liu L; Ren X
Clin Lung Cancer; 2022 Dec; 23(8):709-719. PubMed ID: 35995696
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
Hou H; Wang Y; Sun D; Zhu J; Jiang M; Zhang X; Zhou N; Zhang C; Li T; Zhang X
Invest New Drugs; 2023 Feb; 41(1):86-92. PubMed ID: 36508040
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
Gao S; Li N; Gao S; Xue Q; Ying J; Wang S; Tao X; Zhao J; Mao Y; Wang B; Shao K; Lei W; Wang D; Lv F; Zhao L; Zhang F; Zhao Z; Su K; Tan F; Gao Y; Sun N; Wu D; Yu Y; Ling Y; Wang Z; Duan C; Tang W; Zhang L; He S; Wu N; Wang J; He J
J Thorac Oncol; 2020 May; 15(5):816-826. PubMed ID: 32036071
[TBL] [Abstract][Full Text] [Related]
12. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.
Zhang X; Shao M; Yao J; Zhao L; Li L; Chen M; Zhang Y; Liu H; Chen Z; Li B; Wu Z; Fan J; Qiu F
Future Oncol; 2024 Jan; 20(3):121-129. PubMed ID: 38353107
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
Jiang W; Zhou Y; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Guo H; Minervini F; Bongiolatti S; Yang N; Zhang Y; Tao M
Transl Lung Cancer Res; 2022 Apr; 11(4):647-655. PubMed ID: 35529791
[TBL] [Abstract][Full Text] [Related]
17. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H
Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
